Published Date:2024-03-29 Original Link:https://www.onenessbio.com/en/news_detail279_4.htm No 1 Date of announcement 2024/03/29 Time of announcement 18:08:07 Subject Submission of a phase II clinical trial protocol to Taiwan FDA for subcutaneous injection formulation of FB825 in patients with moderate-to-severe atopic dermatitis To which item it meets paragraph 10 Date of events 2024/03/29 Statement Date of occurrence of the...Read More